Enfusion, Inc. (NYSE:ENFN) Insider Bronwen Bastone Sells 3,126 Shares

Enfusion, Inc. (NYSE:ENFN - Get Free Report) insider Bronwen Bastone sold 3,126 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total transaction of $35,573.88. Following the completion of the transaction, the insider now directly owns 221,875 shares in the company, valued at $2,524,937.50. This trade represents a 1.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Bronwen Bastone also recently made the following trade(s):

• On Monday, March 3rd, Bronwen Bastone sold 2,064 shares of Enfusion stock. The stock was sold at an average price of $11.48, for a total value of $23,694.72.
• On Tuesday, January 7th, Bronwen Bastone sold 809 shares of Enfusion stock. The stock was sold at an average price of $10.13, for a total value of $8,195.17.

Enfusion Stock Performance

ENFN stock traded up $0.04 during mid-day trading on Tuesday, reaching $11.15. The company had a trading volume of 780,007 shares, compared to its average volume of 1,156,687. Enfusion, Inc. has a fifty-two week low of $7.83 and a fifty-two week high of $11.80. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of 278.69, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95. The firm has a fifty day simple moving average of $10.99 and a 200 day simple moving average of $9.92.

Remove Ads

Enfusion (NYSE:ENFN - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). The firm had revenue of $52.94 million for the quarter, compared to analyst estimates of $53.98 million. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. As a group, analysts predict that Enfusion, Inc. will post 0.06 earnings per share for the current year.

Institutional Trading of Enfusion

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Centiva Capital LP raised its position in shares of Enfusion by 5.0% during the 3rd quarter. Centiva Capital LP now owns 25,596 shares of the company's stock worth $243,000 after acquiring an additional 1,227 shares in the last quarter. Harbor Capital Advisors Inc. lifted its position in shares of Enfusion by 12.4% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company's stock worth $113,000 after buying an additional 1,315 shares during the last quarter. Mackenzie Financial Corp boosted its holdings in shares of Enfusion by 4.8% in the 4th quarter. Mackenzie Financial Corp now owns 31,271 shares of the company's stock valued at $322,000 after buying an additional 1,434 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Enfusion by 5.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,070 shares of the company's stock valued at $289,000 after buying an additional 1,567 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in Enfusion by 3.0% during the 4th quarter. Rhumbline Advisers now owns 62,464 shares of the company's stock worth $643,000 after acquiring an additional 1,796 shares in the last quarter. 81.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Stifel Nicolaus increased their price target on Enfusion from $11.00 to $13.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. William Blair reaffirmed a "market perform" rating on shares of Enfusion in a research report on Monday, January 13th. Finally, Piper Sandler increased their price target on shares of Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $11.13.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.